
|Videos|July 9, 2018
Treating AML With Myelodysplasia-Related Changes
Treating AML With Myelodysplasia-Related Changes
Advertisement
Case: A 68-Year-Old Man With Newly-diagnosed AML
- A 68-year-old man went to the emergency room with complaints of dizziness and chest pain
- Myocardial infarction diagnosed and managed in hospital
- During stay, CBC revealed decreased neutrophils but increased total white blood cell count
- When stable from MI, he was referred for specialist consultation
- Patient history and physical exam:
- Reported fatigue, shortness of breath with minor exertion, and unexplained weight loss that have worsened over the past 2 months
- Over the 6 months, has experienced three upper respiratory infections, often with mild fever, that were refractory to treatment, but which he attributed to being a former smoker
- No history of cancer or cytotoxic treatment
- Laboratory findings:
- Absolute neutrophil count: 600 cells/µL; WBC: 85,000 cells/µL
- Peripheral blood shows poorly differentiated myeloid cells
- 25% blasts in peripheral blood
- Cytogenetic abnormalities: chromosome 5 (del[5q])
- Diagnosed with acute myeloid leukemia with myelodysplastic-related changes
- Received Vyxeos (CTX-351) induction therapy, followed by consolidation
- Experienced complete response and underwent HSCT
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5









































